Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, February 03, 2021
Lonza has expanded its human primary cell offerings with the launch of fully customizable cryopreserved Leukopaks.
read more
Lonza announced today the construction of a new small molecule manufacturing complex at its Visp (CH) site.
read more
Monday, February 03, 2020
Lonza announced a clinical manufacturing agreement with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.
read more
Tuesday, September 24, 2024
Lonza announced the signature of a long-term commercial supply agreement for CASGEVY® (exagamglogene autotemcel).
read more
ValenzaBio, a biopharmaceutical company developing monoclonal antibody therapeutics for autoimmune and inflammatory indications, and Lonza announced that the companies have a manufacturing agreement in place.
read more
Thursday, September 08, 2022
Lonza agrees to cooperate with Touchlight to aid in genetic medicine advancement. Through this collaboration, Lonza will have the ability to integrate an additional,
read more
Lonza announced that it is enhancing its bioconjugation offering through an agreement with Singzyme, a company focused on developing enzymes for protein ligation.
read more
Thursday, February 11, 2016
Lonza Houston, Inc., a viral gene therapy manufacturing company, and Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, have entered into a Manufacturing ...
read more
Lonza has announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna.
read more
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
read more
Tuesday, November 30, 2021
Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced a framework ...
read more
ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, announced a framework collaboration agreement to help ALSA’s portfolio of pre-...
read more
Wednesday, December 15, 2021
Lonza, a global cell and gene therapy manufacturer, and Agilent Technologies, a provider of life sciences analytics, diagnostics, and applied chemical technologies, announced a collaboration that has the potential to transform the way personalized ...
read more
Thursday, September 17, 2015
Physician-scientist Frank M. Longo, MD, PhD, has been named the inaugural winner of the Alzheimer's Drug Discovery Foundation's (ADDF) Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery, the first prize to specifically recognize ...
read more
Longhorn Vaccines & Diagnostics and Pharmco have combined to rapidly accelerate coronavirus testing and detection which are critical to combating the global COVID-19 pandemic.
read more